Renaissance Capital logo

Cadrenal Therapeutics Filed Terms, Nasdaq: CVKD

Phase 3-ready biotech developing an acquired therapy for thrombosis and AFib.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. We secured the rights to tecarfarin on April 1, 2022 via an asset purchase agreement from HESP LLC, a wholly owned subsidiary of Horizon Technology Finance Corporation. In 2019, the United States Food and Drug Administration, or FDA, provided input on the Phase 3 trial design for tecarfarin, which was submitted by Espero, the previous owner of tecarfarin. We intend to submit our Phase 3 trial design to the FDA using the same protocol that was submitted by Espero. Assuming the FDA accepts our Phase 3 trial design, we intend to commence the Phase 3 pivotal trial in the second half of 2023. However, there can be no assurance that the trial design will be accepted by the FDA. We are pursuing regulatory approval of tecarfarin as an individual treatment, although we might evaluate, in consultation with the FDA, other potential uses in the future.
more less
IPO News for Cadrenal Therapeutics
more
IPO Data
IPO File Date 09/22/2022
Offer Price
Price Range $5.00 - $5.00
Offer Shares (mm) 2.0
Deal Size ($mm) $10
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $5.00 - $5.00
Offer Shares (mm) 2.0
Deal Size ($mm) $10
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Ponte Vedra, FL
Founded 2022
Employees 1
Website www.cadrenal.com